1 Insights into the comorbidity between type **2** diabetes and osteoarthritis.

2 Authors

3 Ana Luiza de S. V. Arruda,^{1,2,4} April Hartley,⁵ Georgia Katsoula,^{1,4} George Davey Smith,⁵ Andrew P.

- 4 Morris,^{1,6} Eleftheria Zeggini^{1,3,11,12,*}
- 6 Affiliations
- 7 ¹Institute of Translational Genomics, Helmholtz Munich, Neuherberg, 85764, Germany
- 8 ²Munich School for Data Science, Helmholtz Munich, Neuherberg, 85764, Germany
- ³TUM school of medicine, Technical University Munich and Klinikum Rechts der Isar, Munich, 81675,
 Germany
- ⁴Technical University of Munich (TUM), School of Medicine, Graduate School of Experimental Medicine,
- 12 Munich, 81675, Germany
- 13 ⁵MRC Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, United Kingdom
- 14 ⁶Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The
- 15 University of Manchester, Manchester, M13 9PT, United Kingdom
- 16

5

17 Authors list footnote

- 18 ¹¹ Senior authors
- 19 ¹² Lead contact
- 20
- 21 Corresponding authors
- 22 eleftheria.zeggini@helmholtz-muenchen.de
- 23

24 Abstract

25 Multimorbidity is a rising public health challenge with important implications for health management 26 and policy. The most common multimorbidity pattern is for the combination of cardiometabolic and 27 osteoarticular diseases. Here, we study the genetic underpinning of the comorbidity between type 2 28 diabetes and osteoarthritis. We find genome-wide genetic correlation between the two diseases, and 29 robust evidence for association signal colocalization at 18 genomic regions. We integrate multi-omics 30 and functional information to resolve the colocalizing signals, and identify high-confidence effector 31 genes, including FTO and IRX3, which provide proof-of-concept insights into the epidemiologic link 32 between obesity and both diseases. We find enrichment for lipid metabolism and skeletal formation 33 pathways for signals underpinning the knee and hip osteoarthritis comorbidities with type 2 diabetes, 34 respectively. Causal inference analysis identifies complex effects of tissue-specific gene expression on 35 comorbidity outcomes. Our findings provide insights into the biological basis for the type 2 diabetes-36 osteoarthritis disease co-occurrence.

37

38 Introduction

Multimorbidity is defined as the coexistence of multiple chronic diseases in a single individual [1].
Worldwide, over 50% of the population older than 65 years is affected by more than one long-term
medical condition simultaneously [2]. Commensurate with the rise in life expectancy and average
population age, multimorbidity is an increasing global health challenge. However, the majority of
health and drug development research is focused on treating and/or preventing individual diseases,

- 44 leading to interventions that are currently not optimally designed to assist patients suffering from
- 45 multiple health conditions.

46

47 The most prevalent multimorbidity pattern among women and men is the combination of cardiometabolic and osteoarticular diseases [3], exemplified by the highly prevalent co-occurrence of 48 49 type 2 diabetes and osteoarthritis [4]. Between 2009 and 2016, approximately one in three adults with 50 prediabetes in the US suffered from arthritis [5]. Osteoarthritis is the most common whole-joint 51 chronic disorder, affecting over 520 million people worldwide [6]. It is a degenerative disorder 52 characterized by a local and systemic low-grade inflammation state, irreversible loss of cartilage, and 53 additional bone formation that results in pain, its most prevalent symptom [7]. Across the globe, type 54 2 diabetes affects over 430 million people and is characterized by elevated blood glucose levels and 55 insulin resistance [6]. Both osteoarthritis and type 2 diabetes are complex diseases influenced by 56 genetic, demographic and lifestyle factors, such as older age and obesity [8].

57

58 The majority of observational studies have reported a positive epidemiological association between 59 type 2 diabetes and osteoarthritis of the hip or knee [4]. In a meta-analysis including 1,040,175 60 patients, the unadjusted odds ratio (OR) for type 2 diabetes in osteoarthritis patients compared to 61 non-osteoarthritis patients was 1.41 (95% confidence interval (CI)=[1.21, 1.65]) [9]. For type 2 diabetes 62 patients, the overall risk of osteoarthritis was also higher compared to individuals without type 2 63 diabetes (unadjusted OR=1.46, 95%CI=[1.08, 1.96], N=32,137) [9]. Articular joint-specific analyses 64 have shown a stronger link between type 2 diabetes and knee osteoarthritis than hip osteoarthritis 65 [9].

66

Mendelian randomization analyses [10] suggest no causal relation between liability to type 2 diabetes 67 68 and knee osteoarthritis [11], whereas body-mass index (BMI) has been shown to be causal for both 69 diseases [12], [13]. When adjusting for BMI, studies linking type 2 diabetes and osteoarthritis have 70 yielded conflicting results [4], [9], [14]. Considering that obesity is a major risk factor for both diseases 71 studied here, genetic variants associated with different physiological characteristics of increased 72 adiposity are expected to be shared risk variants for the comorbidity. However, those variants could 73 exert their effects on the comorbidity through alternative biological pathways to obesity through horizontal pleiotropy [10]. 74


75

Given the increase of the world's elderly population and the chronic nature of this highly prevalent pair of diseases, understanding their shared genetic background is important in order to identify risk variants and effector genes that could be used as biomarkers or druggable targets for bilateral treatment. Here, we perform a systematic overlap analysis on a genome-wide scale to disentangle the shared genetic aetiology of the type 2 diabetes-osteoarthritis comorbidity, including integration with functional genomics data in relevant cell types, and provide insights into common underpinning mechanisms of disease development, including but not limited to, adiposity.

83 Results

84 Insights into disease biology and treatment targets

We first assessed the genetic correlation between type 2 diabetes ($N_{cases} = 74,124$, $N_{controls} =$ 85 824,006) and osteoarthritis (knee: $N_{cases} = 62,497$, $N_{controls} = 333,557$; hip: $N_{cases} = 36,445$, 86 $N_{controls} = 316,943$) on a genome-wide scale using data from the largest GWAS meta-analyses to 87 88 date (Table S1 and Figure S1). In line with epidemiological evidence, we find greater magnitude of 89 genetic correlation between type 2 diabetes and knee osteoarthritis ($r^2=0.241$, SE=0.028, p=2.65e-18) compared to osteoarthritis of the hip ($r^2=0.078$, SE= 0.029, p=0.008) (Figure 1A). To assess the 90 91 potential for bias due to overlapping samples and different sample sizes, we also performed a 92 permutation-based analysis (empirical p-value for knee=0.005, empirical p-value for hip=0.142) 93 (Figure 1B, Table S1 and Figure S2). Causal inference analyses using Mendelian randomization showed 94 evidence for a non-causal relationship between the two diseases (Table S6), consistent with smaller-95 scale studies in the literature [12].



96 97 Figure 1: Stronger evidence for a genetic correlation between type 2 diabetes and knee osteoarthritis compared to hip 98 osteoarthritis. A) Genetic correlation results between type 2 diabetes (T2D) and knee or hip osteoarthritis (OA). B) 99 Permutation-based testing results for knee OA and hip OA, respectively. The red line is the true correlation.

Using pairwise Bayesian colocalization analyses on genome-wide significant regions for osteoarthritis 100


 $(P = 1.3x10^{-8})$ or type 2 diabetes $(P = 5x10^{-8})$, we found robust evidence (posterior probability \geq 101 0.8) for a shared causal signal between both diseases at 18 genomic loci (Table S2 and Figures S5-S22). 102

103


Ten of those loci colocalize with type 2 diabetes for both hip and knee osteoarthritis, two colocalize

104 for hip osteoarthritis only, and six colocalize only for knee osteoarthritis. In three genomic loci, the


- 105 95% credible set for the causal variant from the colocalization analysis consisted of a single variant 106 (Figure 2).
- 107








We incorporated multi-omics and functional information to identify shared high-confidence candidate effector genes for the type 2 diabetes-osteoarthritis comorbidity in the colocalizing loci. Twelve of these showed statistical evidence for colocalization with gene expression or protein quantitative trait loci (eQTLs and pQTLs, respectively) from disease-relevant tissues (cartilage chondrocytes, synoviocytes and/or pancreatic beta cells). In total, we analysed 906 genes in the vicinity of colocalizing genomic regions by integrating six lines of complementary evidence (Figure 3 and Table S3).



123 124



We defined 72 genes as likely effector genes for the type 2 diabetes-osteoarthritis comorbidity, as 133 134 they displayed at least one line of supporting evidence for being involved in both diseases. Of the 72 likely effector genes, 19 showed at least three lines of evidence and were defined as high-confidence 135 136 effector genes (Figure 4). These represent relevant candidates for further functional and clinical 137 research. Eleven of these have not previously been defined as high-confidence genes for either 138 disease. For two of the high-confidence genes, APOE and WSCD2, the 95% credible set for the causal 139 variant from the colocalization analysis includes missense variants, namely rs429358 and rs3764002. 140 Six out of 19 high-confidence effector genes are the nearest gene to the lead variant of the respective 141 colocalizing genomic locus: WSCD2, TCF7L2, JADE2, GLIS3, FTO and APOE (Figure S3).

142

143 We searched the druggable genome for the druggability status of the likely effector genes for the type 2 diabetes and osteoarthritis comorbidity [15]. Sixteen out of 72 genes were included in the druggable 144 145 genome (Table S4). Of these, 6 genes are tier 1 druggable targets (GIPR, TPO, PAK1, SIGMAR1, CTSB, 146 NOS3), i.e., they are targets of drugs that have market authorization or are in clinical development. 147 The GIPR agonist tirzepatide was recently approved for the treatment of type 2 diabetes in adults. It 148 has glucose-lowering effects and has been shown to increase insulin sensitivity [16]. The PAK1 149 inhibitor fostamatinib has been approved for the treatment of chronic immune thrombocytopenia 150 [17]. It is also in clinical trial for the treatment of rheumatoid arthritis in order to alleviate the degree 151 of inflammation of the joints [18]. SIGMAR1 is a target of multiple approved drugs, including 152 pentazocine, which is an analgesic used to treat moderate to severe pain. Naltrexone, an antagonist 153 used in opioid overdose that also targets SIGMAR1, is being investigated for treating obesity [19], [20]. 154 The TPO gene encodes the thyroid peroxidase protein, which is the target of several approved drugs 155 for the treatment of hyperthyroidism. One of these, the thyroid hormone dextrothyroxine, has been 156 shown to lower serum levels of cholesterol in humans, but the interventional study has been 157 discontinued due to serious adverse effects [21].

158

159 The 72 likely effector genes were enriched for several metabolic and cellular process, and for lipid 160 localization and storage pathways. Hip osteoarthritis-related likely effector genes were enriched for 161 bone development pathways and metabolic processes. The 19 high-confidence effector genes were 162 enriched for biological pathways related to diet and obesity (response to caloric restriction and Fto 163 obesity variant mechanism) and for regulation of cell differentiation. The high-confidence genes related to hip osteoarthritis were enriched for the Fto obesity variant mechanism pathway, regulation 164 165 of lipid localization, and for a biological pathway related to skeletal formation (proximal/distal pattern 166 formation) (Table S5 and Figure S4). These results provide biological support for the link between 167 obesity and both diseases, and for the association between bone development and hip osteoarthritis 168 [7].

169


170 Disentangling the effect of obesity

171 To explore the role of obesity on the co-occurrence of type 2 diabetes and osteoarthritis, we studied 172 four different measures that capture different aspects of obesity and adiposity: BMI, waist-to-hip 173 ratio, whole body fat mass, and body fat percentage. Sixteen out of the 18 genomic regions that 174 colocalized between type 2 diabetes and osteoarthritis show evidence of association or colocalization 175 (PP4 > 0.8) with at least one adiposity-related trait (Table S9). Four high-confidence effector genes 176 reside in the two genomic regions that do not show any evidence of colocalization or association with 177 the analysed measures of adiposity: TMEM176A, RARRES2, SMARCD3 and GLIS3. These may point to 178 alternative biological mechanisms other than adiposity in the comorbidity between type 2 diabetes 179 and osteoarthritis for these colocalizing signals.

180 We investigated whether these adiposity measures were causally associated to the expression of high-181 confidence effector genes in disease-relevant tissues. Within the constraints of the available 182 instruments (Methods), we found evidence of a causal relationship between several adiposity measures and nine high-confidence effector genes (Table S7). For example, we find that all measures of adiposity have a causal effect on higher expression of *IRX3* in synovium or pancreatic islets and on lower expression of *RTN2* in osteoarthritis cartilage. For the high-confidence effector genes located in the two genomic loci that did not show evidence of association or colocalization with adiposity, the

187 direction of effect was not consistent across the different measures employed.

188 We assessed the causal role of BMI-associated variants with tissue-specific effects, selected based on 189 evidence of their colocalization with brain or subcutaneous adipose tissue eQTLs [22]. For type 2 190 diabetes, we replicated previous results and showed that BMI-associated variants influencing genes 191 expressed in brain tissue exert a stronger effect on the disease than adipose-tissue related variants 192 [22], although confidence intervals largely overlapped. For knee osteoarthritis, we observed the same 193 trend (Figure S23). For hip osteoarthritis, the results of the causal inference analysis provide evidence 194 for a stronger effect of BMI-associated variants that colocalize with adipose-tissue eQTLs than with 195 brain eQTLs (Table S10). Our results suggest a similar biological underpinning of the adiposity effect 196 captured by BMI on type 2 diabetes and knee osteoarthritis, but potentially different processes for 197 hip osteoarthritis.



198 199

Figure 4: Overview of the 19 high-confidence effector genes for the type 2 diabetes and osteoarthritis comorbidity. Genes
 are stratified based on the joint affected by osteoarthritis. The scoring of the six biological lines of evidence is depicted on the
 right (Methods.) (OA = osteoarthritis; T2D = type 2 diabetes; molQTL = molecular quantitative trait loci; DEG = differential

expressed genes; KO mice = knockout mice; OMIM = Online Mendelian Inheritance in Man; HC = previously defined high confidence effector genes; missense = missense variant).

205 Insights gained from individual loci

206 FTO and IRX3

The obesity-related *FTO* locus colocalizes for type 2 diabetes and osteoarthritis with a posterior probability of a shared causal variant of over 92% (Figure 5). The 95% credible set from the colocalization analysis consists of multiple variants in high linkage disequilibrium with each other. The risk-increasing alleles for the lead causal variants are the same across type 2 diabetes and osteoarthritis. In addition to *FTO*, this locus is associated with a further high-confidence effector gene, *IRX3*. *IRX3* eQTLs in pancreatic islets colocalize with type 2 diabetes and osteoarthritis genetic signals with a PP4 > 0.8.

214

As shown above, adiposity is causally associated with an increase in *IRX3* expression in pancreatic islets

- and synovium (Table S7A). Here, we performed causal inference analyses between the expression of
- high-confidence genes at this locus and type 2 diabetes or osteoarthritis. We find evidence for a causal
- effect of increased expression of *IRX3* in pancreatic islets on increased risk of type 2 diabetes (OR=1.16;
- 219 95%CI=[1.08, 1.25]; p-value=4.4E-05, F-stat= 16.7).

220 FTO is a high-confidence osteoarthritis effector gene involved in skeletal development, adipogenesis,

221 and neuronal function and development [23]. It is also associated with syndromic human disease 222 growth retardation, developmental delay, and facial dysmorphism (GDFD), which is a lethal autosomal 223 recessive multiple congenital anomaly syndrome [24]. IRX3 is a known functional long-range target of 224 FTO variants associated with obesity [25]. FTO and IRX3 knockout mice show decreased body weight, 225 decreased bone mineral density, and improved glucose tolerance (high bone mineral density is a risk 226 factor for hip and knee osteoarthritis [26]). We expected genes with an adiposity-driven effect to be 227 involved in the shared genetic aetiology of the type 2 diabetes-osteoarthritis comorbidity since obesity 228 constitutes a common risk factor [8].

229

230 TCF7L2

231 TCF7L2 is one of the highest-scoring effector genes. This genomic locus colocalizes for type 2 diabetes 232 and knee osteoarthritis with a posterior probability of a shared causal variant of over 93% (Figure 5). 233 Here, the 95% credible set for the causal variant from the colocalization analysis consists of three 234 variants, which have opposite risk-increasing alleles for type 2 diabetes and knee osteoarthritis (Table 235 S8A). TCF7L2 has not been associated with osteoarthritis at genome-wide significance levels to date 236 (all variants in the credible set achieve nominal significance in the latest knee osteoarthritis GWAS 237 [23]). Genetic variants associated with TCF7L2 expression in pancreatic islets and in osteoarthritis 238 cartilage colocalize with this association signal. For the variants in both 95% credible sets from these 239 colocalization analyses, the risk-increasing alleles for type 2 diabetes are associated with a lower BMI, 240 a lower risk of knee osteoarthritis and an increased expression of TCF7L2 in pancreatic islets and 241 osteoarthritic cartilage.

242

We find evidence that increased BMI causes decreased expression of *TCF7L2* in intact and degraded cartilage (Table S7A). Additionally, we find evidence that an increase in *TCF7L2* expression in pancreatic islets causes an increase in type 2 diabetes risk (OR=5.1; 95%CI=[4.7, 5.4]; p-value<1E-300; F-stat=2018) and a decrease in knee osteoarthritis risk (OR=0.83; 95%CI=[0.77, 0.91]; p-value=1.77E-05; F-stat=18.4). These results are in line with the evidence shown above in support of an opposite

- 248 effect of the genetic variants associated with the expression of *TCF7L2* in knee osteoarthritis and type
- 249 2 diabetes risk.

- 250*TCF7L2* is among the leading signals for type 2 diabetes risk, persisting following adjustment for BMI251[27]. Our results suggest that *TCF7L2* exerts an effect that goes through an alternative biological252pathway to increased BMI. It has been shown that isoforms of *TCF7L2* regulate the expression of genes253related to cartilage destruction in human chondrocytes [28]. *TCF7L2* is a key effector gene of the254Wnt/β-catenin signalling pathway. This pathway plays a role in both type 2 diabetes, through glucose255homeostasis, and in osteoarthritis, through cartilage and bone formation [29], [30].
- 256

257 *TMEM119* and *WSCD2*

258 Two high-confidence effector genes, WSCD2 and TMEM119, reside in the same genomic locus, which 259 colocalizes for type 2 diabetes and knee osteoarthritis with a posterior probability of 99.9% (Figure 5). 260 The 95% credible set consists of two variants: rs1426371 and rs3764002, an intronic and a missense 261 variant (amino acid change: Thr266lle) within WSCD2, respectively. The risk-increasing alleles of both 262 variants are concordant for osteoarthritis of the knee and type 2 diabetes. The variant with the highest posterior probability of being causal for osteoarthritis and type 2 diabetes, rs1426371, has reached 263 264 genome-wide significance levels in the latest knee osteoarthritis GWAS meta-analysis [23]. The 265 missense variant, rs3764002, is associated with BMI, type 2 diabetes, lean mass, and neuropsychiatric 266 disorders including anxiety and schizophrenia. The missense variant is predicted to alter protein 267 function and this alteration is predicted to be damaging by both SIFT (https://sift.bii.a-star.edu.sg) and 268 PolyPhen (http://genetics.bwh.harvard.edu/pph2/).

269

270 WSCD2 eQTLs in degraded osteoarthritis cartilage colocalize with type 2 diabetes and knee 271 osteoarthritis with a posterior probability of 99%. The lead eQTLs are rs142637 and rs3764002. The 272 expression level-increasing alleles are the same as the risk-increasing alleles for both diseases (Table 273 S8B). WSCD2 is also a differentially expressed gene (DEG) in pancreatic islets from diabetes patients 274 versus healthy controls and is downregulated in diabetic islets. Moreover, it has been previously 275 shown that WSCD2 is functionally associated with type 2 diabetes and positively correlated to insulin 276 secretion [31],[32]. Conclusions from causal inference analysis were limited due to weak instruments 277 (F-statistic<10), which can bias causal effect inference (Table S7). Further research is needed to better 278 understand the biological mechanisms through which WSCD2 influences the type 2 diabetes-279 osteoarthritis comorbidity.

280

291

281 TMEM119 is the second most highly scoring high-confidence effector gene. It is a DEG in osteoarthritis 282 cartilage and pancreatic islets and is more highly expressed in degraded compared to intact cartilage 283 and in healthy compared to pancreatic islets. Knockout mice for TMEM119 show phenotypes related 284 to both osteoarthritis and type 2 diabetes, such as decreased body weight, impaired osteoblast 285 differentiation, and decreased compact bone thickness. TMEM119 is related to bone formation by 286 promoting osteoblast differentiation [33]. Fewer osteoblasts can lead to a decrease in compact bone 287 thickness, which is also observed in knockout mice [34]. The over-expression of TMEM119 in degraded 288 cartilage from osteoarthritis patients supports the evidence of an increase in bone formation in later 289 stages of the disease [35]. However, the lower expression of TMEM119 in diabetes compared to 290 healthy pancreatic islets points to further potential mechanisms of effect in the comorbidity.

292 TMEM176A

TMEM176A, also a high-confidence effector gene, has not been previously identified as implicated in either osteoarthritis or type 2 diabetes. This locus colocalizes for type 2 diabetes and knee osteoarthritis with a posterior probability of a shared causal variant of 99.3% (Figure 5). The index variants are rs62492368 and rs7794796, both located in the intron of the *AOC1* gene. rs62492368 is associated with type 2 diabetes [36] and rs7794796 is associated with appendicular lean mass [37]. Type 2 diabetes and osteoarthritis show opposite risk-increasing alleles for all variants in the 95% credible set from the colocalization analysis (Table S8C). These variants colocalize with PP4 > 0.8 between the diseases and eQTL data from pancreatic islets and synovium. The index variants from the
 colocalization with eQTLs also have opposite risk-increasing alleles for both diseases. Similarly, to the
 TCF7L2 locus case, our results suggest that the mechanism through which *TMEM176A* exerts an effect
 on osteoarthritis and type 2 diabetes may have contrary directions.

304

305 We found body fat percentage to be linked to a decrease in the expression of TMEM176A in synovium 306 (Table S7A), albeit with weak instruments (F-statistic<10). Decreased expression of TMEM176A in 307 intact osteoarthritis cartilage and pancreatic islets was associated with reduced risk of type 2 diabetes 308 (pancreatic islets: OR=1.14, 95%CI=[1.07, 1.21], p-value=8.5E-05, F-stat=15.4; cartilage: OR=1.05, 309 95%CI=[1.03, 1.08], p-value=8.5E-05, F-stat=15.4) and increased risk of knee osteoarthritis (pancreatic 310 islets: OR=0.93; 95%CI=[0.87, 0.99]; p-value=0.048; F-stat=3.9, cartilage: OR=0.97; 95%CI=[0.94, 0.99]; 311 p-value=0.048; F-stat=3.9). This genomic locus is one of the two colocalizing regions that do not show 312 any evidence of statistical colocalization between type 2 diabetes, osteoarthritis and the adiposity measures studied here. This suggests that this region, and possibly TMEM176A, acts through an 313 314 alternative biological path to adiposity.

315

316 Results of the causal inference analysis mirror the output of differential expression analyses

conducted in pancreatic islets and osteoarthritic cartilage [38], [39]. While *TMEM176A* is more highly

expressed in diabetes compared to healthy pancreatic islets, an increase of its expression in the same

tissue has a causal effect on increased risk of type 2 diabetes. Similarly, while *TMEM176A* was found to have lower expression in degraded compared to intact cartilage, the reduced expression of this

321 gene in intact cartilage has a causal effect on increased risk of total knee replacement.




Figure 5: Regional association plots of the highlighted colocalizing regions between type 2 diabetes and osteoarthritis. a)
 FTO and IRX3 region; b) TCF7L2 region; c) WSCD2 and TMEM119 region; d) TMEM176A region. The plots are colored based
 on linkage disequilibrium between the lead causal variant and all other variants. (PP4 = posterior probability of a single
 shared causal variant; OA = osteoarthritis; T2D = type 2 diabetes; All OA = osteoarthritis at any site)

327 Discussion

We present an approach to disentangle the shared genetic aetiology between two co-occurring chronic diseases, exemplified through the type 2 diabetes-osteoarthritis comorbidity. Studies have shown a stronger association of BMI with osteoarthritis of the knee than of the hip [12]. We find stronger statistical evidence of a genetic correlation between type 2 diabetes and knee osteoarthritis compared to hip osteoarthritis. By leveraging the latest large-scale GWAS for both diseases, we find robust evidence of colocalization at 18 genomic loci and, by incorporating multi-omics and functional genomics information, we derive a list of 19 high-confidence effector genes for the comorbidity. The majority of genomic loci colocalize for type 2 diabetes and knee, rather than hip, osteoarthritis, in keeping with the genome-wide correlation analysis results.

337

Our findings support the epidemiological link between obesity, osteoarthritis, and type 2 diabetes. In 338 339 this case, only two of the 18 colocalized regions do not colocalize with measures of adiposity. Several 340 of the high-confidence genes are associated with obesity-related traits, including FTO and IRX3. We 341 show that the identified high-confidence effector genes are enriched for biological pathways 342 associated with adiposity. Stratifying the high-confidence effector genes into knee or hip osteoarthritis 343 provides further insight into the biological mechanisms underlying the comorbidity. High-confidence 344 effector genes mostly related to hip osteoarthritis are also enriched for biological pathways of skeletal 345 formation, which underlines the strong link between bone development and hip osteoarthritis [7]. 346 Given that two-thirds of FDA-approved drugs are supported by genetic evidence, we explore the 347 druggable potential of the prioritized genes [40]. We highlight approved drugs currently used for the 348 treatment of diabetes, obesity, pain, and inflammation.

349

350 Observational studies report that the positive association between type 2 diabetes and osteoarthritis 351 persists after adjusting for BMI [9]. As BMI only captures a limited subset of the effect of adiposity on 352 the comorbidity, this could be a source of residual confounding due to measurement error [41] and 353 observed attenuation of association can be underestimated. We performed in-depth analyses to 354 disentangle the role of adiposity on the comorbidity and find evidence that TCF7L2 and TMEM176A 355 exert an effect on type 2 diabetes and osteoarthritis through an alternative biological path. Further 356 examination, including functional studies, is needed to dissect the precise way in which these genes 357 affect the comorbidity.

358

359 Type 2 diabetes and insulin resistance are known to be negatively correlated with bone strength and 360 are also associated with bone fracture [42]. One possible link between bone and lipid metabolism is 361 the fact that osteoblasts and adipocytes share a common progenitor cell in adult bone marrow with a degree of plasticity that can lead to an imbalance between the two cell lineages [43]. In support of 362 363 this link, differentiation regulation of osteoblasts is highlighted by one of the identified high-364 confidence effector genes, TMEM119. In summary, we highlight three potential biological 365 mechanisms underpinning the comorbidity between type 2 diabetes and osteoarthritis: obesity, 366 imbalance between osteoblasts and adipocytes differentiation in adult bone marrow and the Wnt/ β -367 catenin signalling pathway.

368

369 The genetic and functional genomic data employed in this study are biased towards European 370 populations. Going forward, it will be important to expand analyses to data from diverse populations. 371 The eQTL data from pancreatic islets used in the analyses here comprise almost four times as many 372 samples as the eQTL data from chondrocytes. Therefore, molecular QTL analyses for type 2 diabetes-373 relevant tissues were better-powered than for osteoarthritis-relevant tissues. Mendelian 374 randomization and the subsequent sensitivity analyses were conducted within the constraints of 375 available instruments for expression of the high-confidence genes. This was partially because the 376 molecular QTL data used in this work include cis-QTLs only, which restricts the analyses to variants 377 within the vicinity of the genes or proteins of interest. Future studies should include a wider array of 378 (as yet unavailable) genome-wide molecular QTLs, including at the single-cell level.

379

380 We have studied one of the most frequently co-occurring pairs of complex diseases: type 2 diabetes 381 and osteoarthritis. Our findings offer insights into the biological processes underpinning the comorbidity and highlight potential drug repurposing opportunities in addition to new targets. As the
 world population life expectancy continues on an upward trajectory, the challenge of tackling
 multimorbidity will continue to be high on the healthcare agenda. Genomic data-based approaches,
 as exemplified here for type 2 diabetes and osteoarthritis, can help improve our understanding of the
 co-occurrence of chronic conditions.

387

388 Acknowledgements

We thank Lorraine Southam and Konstantinos Hatzikotoulas for their input and support. We also thank the Genetics of Osteoarthritis (GO), the DIAMANTE and the InsPIRE consortia for providing their data.

392

393 Author contributions

E.Z. and A.L.S.V.A conceived and designed the study and wrote the manuscript. A.L.S.V.A and A.H.
performed computation and statistical analyses and produced the figures. A.L.S.V.A, G.D.S, A.H., E.Z.
and A.P.M. performed data interpretation. A.L.S.V.A, G.D.S, A.H., E.Z. G.K, and A.P.M. provided
significant feedback on the methods, results, and manuscript.

398

399 Declaration of interest

A.H. and G.D.S. work in a unit funded by the Medical Research Council (MRC) and the University of
Bristol (MC_UU_00011/1, MC_UU_00011/3). The remaining authors declare no competing interests.

403 Data and code availability

- This paper analyzes existing, publicly available data. These accession numbers for the datasets
 are listed in the key resources table.
- All original code has been deposited at Zenodo and is publicly available as of the date of
 publication. DOIs are listed in the key resources table.
- Any additional information required to reanalyze the data reported in this paper is available
 from the lead contact upon request.
- 410

411 Methods

- 412 Resource availability
- 413 Lead contact

414 Further information requests should be directed to the lead contact, Eleftheria Zeggini 415 (eleftheria.zeggini@helmholtz-muenchen.de).

- 416 Materials availability
- 417 This study did not generate new unique reagents.
- 418 Data and code availability
- This paper analyzes existing, publicly available data. These accession numbers for the datasets
 are listed in the key resources table.

- All original code has been deposited at Zenodo and is publicly available as of the date of
 publication. DOIs are listed in the key resources table.
- Any additional information required to reanalyze the data reported in this paper is available
 from the lead contact upon request.
- 425

426 Methods details

427 Datasets

428 For osteoarthritis, we used the largest GWAS meta-analysis to date, from the Genetics of 429 Osteoarthritis (GO) consortium [23]. In total, it comprises data from 826,690 individuals (177,517 430 cases) from mostly white European ancestry for 11 different osteoarthritis phenotypes. In this study, 431 we used following osteoarthritis phenotypes: knee, hip, knee and/or hip, total knee replacement 432 (TKR), total hip replacement (THR), total joint replacement (TJR), and osteoarthritis at any site (all). A 433 table with the number of cases, controls, and the total patients for each study can be found in Table 434 1. For type 2 diabetes, the GWAS meta-analysis unadjusted for BMI from the DIAMANTE consortium 435 was used [36]. It includes data from 898,130 individuals (74,124 cases) of European ancestry.

436

OA phenotype	Cases	Controls	Total
All	177,517	649,173	826,690
Knee	62,497	333,557	396,054
Knee and/or hip	89,741	400,604	490,345
Hip	36,445	316,943	353,388
TKR	18,200	233,841	252,041
TJR	40,887	327,689	368,576
THR	23,021	296,016	319,037

437 Table 1: an overview of osteoarthritis phenotypes used in this work and the number of cases, controls and the total number
438 of patients included in the corresponding GWAS.

We also employed molecular QTL data from disease-specific tissues. For osteoarthritis, we used eQTL data from intact cartilage (n=95), degenerated cartilage (n=87) and synovium (n=77), as well as pQTL data from intact and degenerated cartilage (n=99) [44]. All samples were collected from osteoarthritis patients. For type 2 diabetes, we used eQTL data from pancreatic islets from the InsPIRE consortium

[45]. In the pancreatic islets data set, 37 patients out of 420 were diabetic.

444 We aligned the effect alleles of all data sets used in this paper by inverting the sign of the effect sizes 445 when a mismatch was detected. Chromosome X was not included in any analysis. All data sets used 446 the Genome Reference Consortium Human Build 37 (GRCh37) assembly.

447

448 *Measures of adiposity*

We used four measures of adiposity: body mass index (BMI), waist-to-hip ratio (WHR) unadjusted for BMI, whole body fat mass and body fat percentage. For BMI (N=806,834) and WHR (N=697,734), we used the latest meta-analysis combining data from the GIANT consortium and the UK biobank [54]. The inverse rank normalized GWAS summary statistics for whole body fat mass (N=330,762) and body fat percentage (N=331,117) were taken from the Neale's Lab website (<u>http://www.nealelab.is/ukbiobank/</u>). For each adiposity phenotype, we looked up the effect and significance of all variants in the

- 455 95% credible set of the colocalized regions between type 2 diabetes and osteoarthritis (Table S9).
- 456
- **457** Quantification and statistical analysis
- 458 Genetic overlap of type 2 diabetes and osteoarthritis phenotypes
- 459 We conducted a linkage disequilibrium (LD) score regression analysis using the LDSC software (v1.0.1)
- 460 with –rg flag to estimate the genetic correlation between each osteoarthritis phenotype and type 2

diabetes (Table S1) [46]. Since the majority of the GWAS used here comprises data of European ancestry individuals only, pre-computed LD scores from the 1000 Genomes European ancestry haplotypes were used [47]. To assess the potential for chance findings when performing multiple statistical analyses, we performed a permutation-based analysis. We randomly permuted the effects (Z-scores) of the variants for the osteoarthritis phenotypes ten thousand times while fixing the effects for type 2 diabetes. Running LD score regression on each permuted data set yielded an empirical pvalue for the genetic correlation of type 2 diabetes and each analysed osteoarthritis phenotype.

468

469 Statistical colocalization analysis

470 We defined regions of 2 Mb (+- 1 Mb) around established independent association signals from each 471 disease. For type 2 diabetes, we selected all primary and secondary independent signals from the BMI unadjusted GWAS (p-value threshold = $5x10^{-8}$). For osteoarthritis, we selected the risk signals for the 472 473 respective phenotype at the adjusted genome-wide significance of $1.3x10^{-8}$. For each osteoarthritis phenotype, we performed regional pairwise statistical colocalization analysis with type 2 diabetes 474 475 using the coloc.abf function from the coloc R package (version 3.2.1) [48]. Colocalization analyses were 476 conducted using estimated regression coefficients (effect sizes) and standard errors (Table S2). In 477 short, this function calculates posterior probabilities for five association configurations under the 478 assumption of a single causal variant per trait. These configurations are summarized in the hypotheses

- 479 below:
 - HO: no trait has a genetic association in the region
 - H1: trait 1 has a genetic association in the region
 - H2: trait 2 has a genetic association in the region
 - *H3:* both traits have a genetic association in the region, but with different causal variants
 - H4: both traits share a genetic association (single causal variant) in the region
- 480

For all osteoarthritis phenotypes, we used the default prior probabilities of the *coloc* R package. We considered evidence for colocalization if the posterior probability of H4 (PP4) > 0.8. For each genomic locus of colocalization, we calculated a 95% credible set for the causal variant by taking the cumulative sum of the variants' posterior probabilities to be causal conditional on H4 being true. LD between the single nucleotide polymorphisms (SNPs) was calculated using plink (version 2.0 alpha) [49] based on the UK biobank [50] and was used for visualizing the results in regional association plots.

487

488 Knockout mouse phenotypes

489 We performed a schematic search for each gene in the vicinity of the colocalized genomic loci that 490 colocalize between type 2 diabetes and osteoarthritis to screen for knockout mice showing 491 phenotypes related to type 2 diabetes or osteoarthritis. The databases used in this scope were the 492 International Mouse Phenotyping Consortium (IMPC) (<u>https://www.mousephenotype.org/</u>), Mouse 493 Genome Informatics (MGI) (http://www.informatics.jax.org/) and Rat Genome Database (RGD) 494 (https://rgd.mcw.edu/) databases. For IMPC and RGD we extracted the knockout mice phenotypes for 495 each potential effector gene using the programmatic data access via their application programming 496 interface (API). For MGI, we used the MGI batch query.

- For type 2 diabetes, we looked for insulin and diabetes-related phenotypes that included the following
 terms: insulin, glucose, diabetes, hyperglycaemia, pancreas, pancreatic, obesity, BMI, body weight,
 body mass, body fat, beta cell, and glucosuria. For osteoarthritis, we looked for musculoskeletal
 phenotypes including the terms skeletal, muscle, bone, osteo, arthritis, muscular, joint, body size,
 growth, stature, and height.
- 502

503 Rare and syndromic human diseases

504 To investigate whether any analysed genes are associated with a monogenic disorder, we extracted 505 data from the Online Mendelian Inheritance in Man (OMIM) (<u>https://omim.org/</u>) using their API. The terms we looked up for osteoarthritis-related phenotypes were bone, muscle, skeleton, osteo,
arthritis, muscular, joint, body size, growth, skeletal, stature, height, Hand-foot-uterus, synostosis,
Martsolf, Warburg, leukodystrophy, squalene, and Finca. For type 2 diabetes we searched for insulin,
glycemia, glucose, diabetes, pancreas, pancreatic, obesity, BMI, body weight, body mass, body fat,
beta cell, glucosuria, Martsolf, aciduria, Aicardi-Goutières, and Finca.

511

512 Differential gene expression

513 We explored if the analysed genes show differential expression for type 2 diabetes and osteoarthritis 514 using published summary statistics from RNA-seq datasets. For osteoarthritis, differential expression 515 was assessed by comparing paired intact and degraded osteoarthritis cartilage from 124 patients [38]. 516 Since the samples were collected within patients, the data is automatically robust against cofactors 517 such as age and population structure. For type 2 diabetes, we used RNA-seq data from surgical 518 pancreatic tissue samples from metabolically phenotyped pancreatectomized patients. Samples were 519 collected from 18 non-diabetic patients and 39 patients that were previously diagnosed with type 2 520 diabetes [39]. The differential expression analysis was based on a linear model with age, sex, and BMI 521 as covariates. We considered genes that changed more than 1.5-fold in either direction and had an 522 adjusted p-value < 0.05 to be differentially expressed between degraded (high-grade) and intact (low-523 grade) osteoarthritis cartilage, and diabetic versus healthy pancreatic islets, for osteoarthritis and type 524 2 diabetes respectively.

525

526 Multi-trait statistical colocalization analysis with eQTL and pQTL data

527 First, we superimposed molecular QTL information from disease-specific tissues by performing multi-528 trait molecular QTL-GWAS colocalization analyses. The analyses were performed only on the variants 529 in the 95% credible set. The input consisted of three summary statistics: one from the type 2 diabetes 530 GWAS, one from the osteoarthritis phenotype GWAS, and one from the disease-relevant tissue 531 molecular QTL data set. Since one variant is tested for multiple genes in an eQTL data set, or multiple 532 proteins for the pQTL data sets, we performed the colocalization gene-wise or protein-wise, 533 respectively, such that for each analysis a single molecular QTL summary statistic is available for each 534 variant. If the 95% credible set consisted only of a single variant, for each gene or protein, we included 535 all variants in a 1 Mb window in the analysis.

- 536 For the multi-trait statistical colocalization analyses, we used the R package HyPrColoc (version 1.0.0) 537 [51]. We conducted regional gene-wise analysis to assess whether all traits colocalize by switching off 538 the Bayesian divisive clustering algorithm (bb.alg=FALSE). In a similar manner to the coloc package, we 539 used HyPrColoc to estimate the posterior probabilities and identify candidate causal genes using 540 multiple traits as input. For consistency, evidence for colocalization was considered at a threshold of 541 0.8 for PP4. The type 2 diabetes and osteoarthritis GWAS meta-analyses share five cohorts. Although 542 the sample overlap, we assumed independence between the data sets, as instructed by the 543 developers of the HyPrColoc package.
- Using the prior knowledge that type 2 diabetes and osteoarthritis colocalize in the analysed genomic loci, we adapted the prior parameters of the *HyPrColoc* algorithm accordingly. The first parameter, *prior.1*, which denotes the probability of a SNP being associated with one trait only, was set to 1e-10, six times smaller than the default. We set the second parameter *prior.2* to 0.7 instead of the default of 0.98. 1-*prior.2* denotes the prior probability of a SNP being associated with an additional trait and 1-(*prior.2*)² with the SNP being associated with the two other traits. LD between SNPs was again

calculated using plink (version 2.0 alpha) [49] based on the UK biobank [50].

550 551

552 Scoring of potential effector genes

553 In genomic loci that colocalized between type 2 diabetes and at least one osteoarthritis phenotype 554 with a PP4 > 0.8, we analysed all genes in a 1 Mb window on either side of the lead variant of the 95%

- 555 credible set. We incorporated orthogonal multi-omics and functional information to derive a list of556 high-confidence effector genes for the type 2 diabetes-osteoarthritis comorbidity.
- 557 Except for the pQTL analysis, all four above-mentioned biological lines of evidence were tested for 558 both osteoarthritis and type 2 diabetes, yielding one separate score for each disease. Additionally, we 559 incorporated information about previously established high-confidence effector genes for the 560 individual diseases. For type 2 diabetes, we defined genes as high-confidence if their top score in the 561 type 2 diabetes knowledge portal was at least 4 (<u>https://t2d.hugeamp.org/</u>). For osteoarthritis we 562 selected genes scored as high-confidence by the GO consortium [23]. Since our analysis overlaps with 563 criteria used to define a gene as high-confidence for the individual diseases, we followed an approach
- to incorporate this information orthogonally: if a gene is high-confidence for a disease, but scored
- 565 zero in our analysis, we updated the respective disease score to one.
- We also looked up all variants in the 95% credible sets searching for any missense variants. This lookup was summarized in an additional score, the missense variant score. The total score was defined as the sum of the osteoarthritis score, the type 2 diabetes score, and the missense variant lookup. If, however, for a gene only the missense variant score is non-zero, the total score was set to zero since
- it is not relevant for the type 2 diabetes-osteoarthritis comorbidity.
- 571 Based on the scoring of the six orthogonal biological lines of evidence, we defined genes as potential 572 effector genes if they showed at least one line of evidence for either one of the diseases. Genes that
- 573 scored at least one line of evidence for osteoarthritis and one for type 2 diabetes were defined as 574 likely effector genes for the comorbidity. High-confidence effector genes were a subset of the likely
- 575 effector genes that scored at least 3 in the total score (Table S3).
- 576 To further analyse our set of effector genes, we grouped them according to the osteoarthritis 577 localisation. If a gene is only associated with osteoarthritis at any site, knee and/or hip osteoarthritis 578 and TJR, then it was considered to be associated with both knee and hip osteoarthritis. If, in addition, 579 an association with knee and/or TKR is observed, then we consider the gene to be mostly associated 580 with knee osteoarthritis. Similarly, if it is associated with hip or THR, then the gene is classified as 581 mostly related to hip osteoarthritis.
- 582
- 583 Multi-trait statistical colocalization analysis with adiposity measures
- 584 In the genomic regions that colocalized between type 2 diabetes and osteoarthritis, we performed multi-trait colocalization analyses between type 2 diabetes, osteoarthritis and the above-mentioned 585 586 measures of adiposity. The analyses were performed only on the variants in the 95% credible set. If 587 the 95% credible set consisted only of a single variant, for each gene or protein, we included all 588 variants in a 1 Mb window on either side of the single variant in the analysis. As for the molecular QTL 589 colocalization, we used the same functions of the R package HyPrColoc (version 1.0.0) and adjusted 590 the prior parameters accordingly (prior.1=1e-10, prior.2=0.7) [51]. For consistency, evidence for 591 colocalization was considered at a threshold of 0.8 for PP4.
- 592

593 Pathway analysis

594 We performed gene set enrichment analyses on the likely and on the high-confidence effector genes 595 stratified by knee or hip osteoarthritis association (Table S5). The number of genes in each set is 596 summarized in Table 2. We used the human resources and the enrichment software from the 597 ConsensusPathDB (<u>http://cpdb.molgen.mpg.de/</u>) to examine the functional annotation of each gene 598 set by testing their enrichment among curated networks in humans [52]. We used the networks from 599 Reactome, KEGG, WikiPathways and Gene Ontology. For the latter, we included the subcategories 600 molecular function, biological processes, and cellular component up to level 4. We required a 601 minimum overlap of 2 genes for enrichment. The significance threshold was set at FDR < 0.05.

602

Gene set	Number of genes
Likely effector genes	72
Likely effector genes related to knee	67
Likely effector genes related to hip	43
HC effector genes	19
HC effector genes related to knee	18
HC effector genes related to hip	10

603

Table 2: number of genes in each gene set (HC =high-confidence)

604 Druggable genome

605 To outline drug repurposing targets, we queried the druggability status of the 72 likely effector genes 606 for the comorbidity. We used the Druggable Genome database, which consists of 4479 genes that are 607 classified into three tiers depending on their progress in the drug development pipeline [15]. Tier 1 608 included 1427 genes that are clinical-phase drug candidates or targets of already approved small 609 molecules and biotherapeutic drugs. Tier 2 consisted of 682 genes that encode targets with known 610 bioactive drug-like small-molecule binding partners and genes with \geq 50% identity (over \geq 75% of the 611 sequence) with approved drug targets. Tier 3 comprised 2370 genes encoding secreted or extracellular 612 proteins, proteins with more distant similarity to approved drug targets, and members of key 613 druggable gene families that were not included in tier 1 or 2. Tier 3 was further subdivided to prioritize genes in proximity (+-50 kbp) to a GWAs SNP from the GWAS catalog and had an extracellular location 614 615 (Tier 3A). Tier 3B is composed of the remaining genes.

For the likely effector genes included in tier 1, we further examined the approved or in clinical trial
drugs using the DrugBank online database (<u>https://www.drugbank.com</u>, accessed on the 1st of August
2022).

619 Causal inference analysis

620 Causal inference was strengthened through use of bi-directional two-sample Mendelian 621 randomization (MR) between type 2 diabetes and all analysed osteoarthritis phenotypes [10]. We used the *TwoSampleMR* R package (version 0.5.6), which is curated by MR-Base [53]. We performed 622 623 causal inference analyses on the full summary statistics (Table S6). For all analyses, instrumental variables (IVs) were selected as the genome-wide significant (p-value $\leq 5x10^{-8}$) and independent 624 625 SNPs from the full data. Independence was defined as LD-based clumped SNPs with a strict LD threshold of $R^2 = 0.001$ over a 10Mb window on either side of the index variant. To assure that the 626 IVs are more strongly related to the exposure than to the outcome, we applied Steiger filtering [10]. 627 628 We applied the inverse variance weighted (IVW) method, which performs a random-effects metaanalysis of the Wald ratios for each SNP and the weighted median (WM) method. Finally, we 629 630 performed sensitivity analyses by testing for heterogeneity based on the Q-statistic using the 631 mr_heterogeneity function from the TwoSampleMR R package. Horizontal pleiotropy was assessed 632 through the intercept of the MR-Egger regression. To account for multiple testing, p-values were 633 adjusted using the false discovery rate (FDR) approach [10].

634

635 Two-step Mendelian randomization

636 We performed a two-step Mendelian randomization analysis between different adiposity measures 637 and type 2 diabetes or osteoarthritis using *cis* expression QTLs (eQTLs) of each high-confidence 638 effector gene in disease-relevant tissues as mediators (Table S7) [55]. In the first step, we assess 639 whether adiposity is causal for the expression of our genes in the respective analysed tissues. To 640 assure independence of IVs between the two steps, we excluded independent eQTLs from the risk 641 variants of each adiposity measure. Independence was defined by local LD-based clumping with $R^2 =$

642 0.001 over a 10Mb window on either side of the index variant.

643 For the second step, we used independent genetics variants associated to each high-confidence gene 644 as IVs and conducted a two-sample MR analysis between each of our genes and type 2 diabetes or 645 osteoarthritis. For each analysed tissue and each gene-disease pair, we conducted one MR analysis 646 using the TwoSampleMR R package (version 0.5.6) [53]. If only one SNP was available after clumping 647 and harmonizing the data, we employed the Wald ratio method. If more than one SNP remained after 648 the pre-processing steps, we applied the IVW method and tested for heterogeneity with the mr_heterogeneity function. Moreover, if more than three SNPs were used for the causal inference 649 650 analysis, we also tested for horizontal pleiotropy through MR-Egger regression. Additionally, we estimated the F-statistics from summary level data as $mean(beta^2/se^2)$ to assess the strength of the 651 652 IVs [10]. Finally, we adjusted the p-values for multiple testing using the FDR approach.

653 Tissue fractionation

- 654 We determined the tissue-specific role of BMI in both osteoarthritis and type 2 diabetes using MR 655 restricted to BMI instruments colocalizing with eQTLs in brain and adipose tissue, respectively, as 656 described in [22] (Table S10). Briefly, summary-level MR was performed restricted to the 86 adipose 657 tissue colocalizing SNPs and the 140 brain tissue colocalizing SNPs, where the numerator of the Wald 658 ratio is the SNP effect on osteoarthritis or type 2 diabetes and the denominator is the effect estimate 659 for the SNP on BMI from a GWAS meta-analysis of UK Biobank and the GIANT consortium [56] available at the MR-Base platform [53]. Osteoarthritis summary statistics were extracted from the latest GWAS 660 661 of hip and knee osteoarthritis from the GO consortium [23]. Type 2 diabetes summary statistics were 662 extracted from the latest European DIAMANTE consortium GWAS [36].
- 663 We used inverse variance weighted meta-analysis of the individual SNP Wald ratios to estimate the 664 causal effects of adipose tissue-instrumented BMI and brain tissue-instrumented BMI on each 665 outcome. As sensitivity analyses, we performed MR-Egger to determine the potential role of 666 pleiotropic effects (i.e. mediated via BMI-independent pathways), which gives a pleiotropy robust estimate of the causal effect assuming that there is no correlation between instrument strength (i.e. 667 668 the association of the SNP with BMI) and the pleiotropic effect [10]. We also performed weighted 669 median analysis, which gives an unbiased estimate of the causal effect as long as less than 50% of the 670 SNPs are invalid instruments [57]. We performed a z-test to assess the effect difference between 671 adipose and brain tissue-instrumented BMI MR analyses.

672 Supplemental information titles

- 673 **Table S1**: Genetic correlation matrix for type 2 diabetes and osteoarthritis.
- Table S2: Overview of colocalized genomic loci between type 2 diabetes and osteoarthritis with
 additional information about colocalization with molecular QTLs from disease-relevant tissues.
- Table S3A: Scoring of all genes in a 1Mb window on either side of the lead variant of the 18
 colocalized regions between type 2 diabetes and osteoarthritis.
- 678 Table S3B: Overview of scoring of likely effector genes for the type 2 diabetes and osteoarthritis679 comorbidity.
- **Table S3C**: Overview of scoring of high confidence effector genes for the type 2 diabetes andosteoarthritis comorbidity.
- Table S4: Likely effector genes for the type 2 diabetes and osteoarthritis comorbidity included in thedruggable genome.

- Table S5A: Results of the pathway analyses of the high confidence effector genes for the type 2
 diabetes-osteoarthritis comorbidity stratified by knee or hip association.
- **Table S5B**: Results of the pathway analyses of the likely effector genes for the type 2 diabetes osteoarthritis comorbidity stratified by knee or hip association.
- Table S6A: Results of bidirectional two-sample Mendelian randomization analyses between type 2
 diabetes and osteoarthritis.
- **Table S6B**: Steiger-filtered results of bidirectional two-sample Mendelian randomization analyses
 between type 2 diabetes and osteoarthritis.
- Table S7A: First step results of two-step Mendelian randomization analysis between adiposity
 measures and gene expression of high confidence effector genes for the type 2 diabetes and
 osteoarthritis comorbidity in disease-relevant tissues.
- Table S7B: Second step results of two-step Mendelian randomization analysis between gene
 expression of high confidence effector genes for the type 2 diabetes and osteoarthritis comorbidity
 in disease-relevant tissues and either one of the diseases.
- Table S9A: Multi-trait colocalization between type 2 diabetes, osteoarthritis and BMI for regions that
 colocalized between type 2 diabetes and osteoarthritis.
- **Table S9B**: Direction of effect and p-value of variants in the 95% credible set of the colocalized
 regions for the comorbidity.
- Table S10: Results of two-sample Mendelian randomization analyses between type 2 diabetes or
 osteoarthritis and BMI risk variants associated with eQTLs in brain and subcutaneous adipose tissue.

705 References

- K. Nicholson, T. T. Makovski, L. E. Griffith, P. Raina, S. Stranges, and M. van den Akker,
 "Multimorbidity and comorbidity revisited: refining the concepts for international health
 research," *Journal of Clinical Epidemiology*, vol. 105. Elsevier USA, pp. 142–146, Jan. 01, 2019.
 doi: 10.1016/j.jclinepi.2018.09.008.
- 710 [2] H. Nguyen, G. Manolova, C. Daskalopoulou, S. Vitoratou, M. Prince, and A. M. Prina,
 711 "Prevalence of multimorbidity in community settings: A systematic review and meta-analysis
 712 of observational studies", doi: 10.1177/2235042X19870934.
- 713 [3] D. L. Bezerra de Souza *et al.*, "Multimorbidity and its associated factors among adults aged 50
 714 and over: A cross-sectional study in 17 European countries," *PLoS One*, vol. 16, no. 2, p.
 715 e0246623, Feb. 2021, doi: 10.1371/JOURNAL.PONE.0246623.
- M. F. Williams, D. A. London, E. M. Husni, S. Navaneethan, and S. R. Kashyap, "Type 2 diabetes and osteoarthritis: A systematic review and meta-analysis," *Journal of Diabetes and its Complications*, vol. 30, no. 5. Elsevier Inc., pp. 944–950, Jul. 01, 2016. doi: 10.1016/j.jdiacomp.2016.02.016.
- M. Sandoval-Rosario *et al.*, "Prevalence of Arthritis Among Adults with Prediabetes and
 Arthritis-Specific Barriers to Important Interventions for Prediabetes United States, 2009–
 2016," *MMWR Morb Mortal Wkly Rep*, vol. 67, no. 44, pp. 1238–1241, Nov. 2019, doi:
 10.15585/MMWR.MM6744A4.

- T. Vos *et al.*, "Global burden of 369 diseases and injuries in 204 countries and territories,
 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019," *The Lancet*,
 vol. 396, pp. 1204–1222, 2020, doi: 10.1016/S0140-6736(20)30925-9.
- 727 [7] J. Martel-Pelletier *et al.*, "Osteoarthritis," *Nature Reviews Disease Primers 2016 2:1*, vol. 2, no.
 728 1, pp. 1–18, Oct. 2016, doi: 10.1038/nrdp.2016.72.
- [8] N. Veronese *et al.*, "Type 2 diabetes mellitus and osteoarthritis Europe PMC Funders Group",
 doi: 10.1016/j.semarthrit.2019.01.005.
- K. Louati, C. Vidal, F. Berenbaum, and J. Sellam, "Association between diabetes mellitus and osteoarthritis: Systematic literature review and meta-analysis," *RMD Open*, vol. 1, no. 1. BMJ
 Publishing Group, p. e000077, Jan. 01, 2015. doi: 10.1136/rmdopen-2015-000077.
- [10] E. Sanderson *et al.*, "Mendelian randomization," *Nature Reviews Methods Primers 2022 2:1*,
 vol. 2, no. 1, pp. 1–21, Feb. 2022, doi: 10.1038/s43586-021-00092-5.
- Z. Cui, H. Feng, B. He, Y. Xing, Z. Liu, and Y. Tian, "Type 2 Diabetes and Glycemic Traits Are Not
 Causal Factors of Osteoarthritis: A Two-Sample Mendelian Randomization Analysis," *Front Genet*, vol. 0, p. 1726, Jan. 2021, doi: 10.3389/FGENE.2020.597876.
- [12] E. Zengini *et al.*, "Genome-wide analyses using UK Biobank data provide insights into the
 genetic architecture of osteoarthritis," *Nat Genet*, vol. 50, no. 4, pp. 549–558, Apr. 2018, doi:
 10.1038/s41588-018-0079-y.
- 742 [13] M. v. Holmes *et al.*, "Causal effects of body mass index on cardiometabolic traits and events:
 743 A Mendelian randomization analysis," *Am J Hum Genet*, vol. 94, no. 2, pp. 198–208, Feb.
 744 2014, doi: 10.1016/j.ajhg.2013.12.014.
- A. Khor, C. A. Ma, C. Hong, L. L. Y. Hui, and Y. Y. Leung, "Diabetes mellitus is not a risk factor
 for osteoarthritis," *RMD Open*, vol. 6, no. 1, p. e001030, Feb. 2020, doi: 10.1136/RMDOPEN2019-001030.
- 748 [15] C. Finan *et al.*, "The druggable genome and support for target identification and validation in
 749 drug development," *Sci Transl Med*, vol. 9, no. 383, Mar. 2017, doi:
 750 10.1126/SCITRANSLMED.AAG1166/SUPPL_FILE/AAG1166_TABLE_S1.ZIP.
- [16] J. P. Frías, "Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes," *Expert Rev Endocrinol Metab*, vol. 15, no. 6, pp. 379–394, Nov. 2020, doi:
 10.1080/17446651.2020.1830759.
- [17] S. Braselmann *et al.*, "R406, an orally available spleen tyrosine kinase inhibitor blocks fc
 receptor signaling and reduces immune complex-mediated inflammation," *J Pharmacol Exp Ther*, vol. 319, no. 3, pp. 998–1008, 2006, doi: 10.1124/JPET.106.109058.
- Y. Tanaka, D. Millson, S. Iwata, and S. Nakayamada, "Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II
 OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study," *Rheumatology*, vol. 60, no. 6, pp. 2884–2895, Jun.
 2021, doi: 10.1093/RHEUMATOLOGY/KEAA732.
- L. Ray, P. Chin, and K. Miotto, "Naltrexone for the treatment of alcoholism: clinical findings,
 mechanisms of action, and pharmacogenetics," *CNS Neurol Disord Drug Targets*, vol. 9, no. 1,
 pp. 13–22, Jun. 2010, doi: 10.2174/187152710790966704.

- [20] I. J. Onakpoya, J. J. Lee, K. R. Mahtani, J. K. Aronson, and C. J. Heneghan, "Naltrexone–
 bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of
 unpublished clinical study reports," *Br J Clin Pharmacol*, vol. 86, no. 4, pp. 646–667, Apr.
 2020, doi: 10.1111/BCP.14210.
- 769 [21] B. R. Gauthier *et al.*, "Thyroid hormones in diabetes, cancer, and aging," *Aging Cell*, vol. 19,
 770 no. 11, p. e13260, Nov. 2020, doi: 10.1111/ACEL.13260.
- [22] G. M. Leyden *et al.*, "Harnessing tissue-specific genetic variation to dissect putative causal
 pathways between body mass index and cardiometabolic phenotypes," *The American Journal*of Human Genetics, vol. 109, pp. 240–252, 2022, doi: 10.1016/j.ajhg.2021.12.013.
- C. G. Boer *et al.*, "Deciphering osteoarthritis genetics across 826,690 individuals from 9
 populations," *Cell*, Aug. 2021, doi: 10.1016/J.CELL.2021.07.038.
- S. Boissel *et al.*, "Loss-of-Function Mutation in the Dioxygenase-Encoding FTO Gene Causes
 Severe Growth Retardation and Multiple Malformations," *Am J Hum Genet*, vol. 85, no. 1, pp.
 106–111, Jul. 2009, doi: 10.1016/J.AJHG.2009.06.002/ATTACHMENT/64B765DE-D8B9-46E8BBE3-45057DED616B/MMC1.PDF.
- 780 [25] S. Smemo *et al.*, "Obesity-associated variants within FTO form long-range functional
 781 connections with IRX3," *Nature*, vol. 507, no. 7492, pp. 371–375, Mar. 2014, doi:
 782 10.1038/nature13138.
- A. Hartley *et al.*, "Using multivariable Mendelian randomization to estimate the causal effect
 of bone mineral density on osteoarthritis risk, independently of body mass index," *Int J Epidemiol*, vol. 2021, pp. 1–14, Dec. 2021, doi: 10.1093/IJE/DYAB251.
- L. del Bosque-Plata, E. Martínez-Martínez, M. Á. Espinoza-Camacho, and C. Gragnoli, "The
 Role of TCF7L2 in Type 2 Diabetes," *Diabetes*, vol. 70, no. 6, pp. 1220–1228, Jun. 2021, doi:
 10.2337/DB20-0573.
- 789 [28] J. S. Rockel *et al.*, "Hedgehog inhibits β-catenin activity in synovial joint development and
 790 osteoarthritis," *J Clin Invest*, vol. 126, no. 5, pp. 1649–1663, May 2016, doi:
 791 10.1172/JCI80205.
- 792 [29] T. Jin, "Current Understanding on Role of the Wnt Signaling Pathway Effector TCF7L2 in
 793 Glucose Homeostasis," *Endocr Rev*, vol. 37, no. 3, pp. 254–277, Jun. 2016, doi:
 794 10.1210/ER.2015-1146.
- A. B. Blom, P. L. van Lent, P. M. van der Kraan, and W. B. van den Berg, "To Seek Shelter from
 the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy," *Curr Drug Targets*, vol. 11, no. 5, pp. 620–629, Mar. 2010, doi: 10.2174/138945010791011901.
- A. Mahajan *et al.*, "Refining the accuracy of validated target identification through coding
 variant fine-mapping in type 2 diabetes," *Nat Genet*, vol. 50, no. 4, p. 559, Apr. 2018, doi:
 10.1038/S41588-018-0084-1.
- [32] J. Taneera *et al.*, "Identification of novel genes for glucose metabolism based upon expression
 pattern in human islets and effect on insulin secretion and glycemia," *Hum Mol Genet*, vol.
 24, no. 7, pp. 1945–1955, Apr. 2015, doi: 10.1093/HMG/DDU610.

- K. Mizuhashi *et al.*, "OBIF, an osteoblast induction factor, plays an essential role in bone
 formation in association with osteoblastogenesis," *Dev Growth Differ*, vol. 54, no. 4, pp. 474–
 480, May 2012, doi: 10.1111/J.1440-169X.2012.01333.X.
- 807 [34] S. I. Harada and G. A. Rodan, "Control of osteoblast function and regulation of bone mass,"
 808 *Nature 2003 423:6937*, vol. 423, no. 6937, pp. 349–355, May 2003, doi:
 809 10.1038/nature01660.
- [35] N. Maruotti, A. Corrado, and F. P. Cantatore, "Osteoblast role in osteoarthritis pathogenesis,"
 J Cell Physiol, vol. 232, no. 11, p. 2957, Nov. 2017, doi: 10.1002/JCP.25969.
- 812 [36] A. Mahajan *et al.*, "Fine-mapping type 2 diabetes loci to single-variant resolution using high813 density imputation and islet-specific epigenome maps," *Nat Genet*, vol. 50, no. 11, pp. 1505–
 814 1513, Nov. 2018, doi: 10.1038/s41588-018-0241-6.
- 815 [37] A. I. Hernandez Cordero *et al.*, "Genome-wide Associations Reveal Human-Mouse Genetic
 816 Convergence and Modifiers of Myogenesis, CPNE1 and STC2," *The American Journal of*817 *Human Genetics*, vol. 105, no. 6, pp. 1222–1236, Dec. 2019, doi:
 818 10.1016/J.AJHG.2019.10.014.
- [38] G. Katsoula *et al.*, "A molecular map of long non-coding RNA expression, isoform switching
 and alternative splicing in osteoarthritis," *Hum Mol Genet*, vol. 00, pp. 1–16, Jan. 2022, doi:
 10.1093/HMG/DDAC017.
- L. Wigger *et al.*, "Multi-omics profiling of living human pancreatic islet donors reveals
 heterogeneous beta cell trajectories towards type 2 diabetes," *Nature Metabolism 2021 3:7*,
 vol. 3, no. 7, pp. 1017–1031, Jun. 2021, doi: 10.1038/s42255-021-00420-9.
- [40] D. Ochoa, M. Karim, M. Ghoussaini, D. G. Hulcoop, E. M. McDonagh, and I. Dunham, "Human
 genetics evidence supports two-thirds of the 2021 FDA-approved drugs.," *Nat Rev Drug Discov*, Jul. 2022, doi: 10.1038/D41573-022-00120-3.
- [41] Z. Fewell, G. Davey Smith, and J. A. C. Sterne, "The impact of residual and unmeasured
 confounding in epidemiologic studies: a simulation study," *Am J Epidemiol*, vol. 166, no. 6, pp.
 646–655, Sep. 2007, doi: 10.1093/AJE/KWM165.
- [42] A. K. Picke, G. Campbell, N. Napoli, L. C. Hofbauer, and M. Rauner, "Update on the impact of
 type 2 diabetes mellitus on bone metabolism and material properties," *Endocr Connect*, vol.
 83. 8, no. 3, p. R55, 2019, doi: 10.1530/EC-18-0456.
- [43] A. D. Berendsen and B. R. Olsen, "Osteoblast-adipocyte lineage plasticity in tissue
 development, maintenance and pathology," *Cell Mol Life Sci*, vol. 71, no. 3, pp. 493–497, Feb.
 2014, doi: 10.1007/S00018-013-1440-Z.
- 837[44]J. Steinberg *et al.*, "A molecular quantitative trait locus map for osteoarthritis," Nature838Communications 2021 12:1, vol. 12, no. 1, pp. 1–11, Feb. 2021, doi: 10.1038/s41467-021-83921593-7.
- [45] A. Viñuela, "Genetic variant effects on gene expression in human pancreatic islets and their
 implications for T2D", doi: 10.1038/s41467-020-18581-8.
- [46] B. K. Bulik-Sullivan *et al.*, "LD Score regression distinguishes confounding from polygenicity in
 genome-wide association studies," *Nature Genetics 2015 47:3*, vol. 47, no. 3, pp. 291–295,
 Feb. 2015, doi: 10.1038/ng.3211.

- 845 [47] A. Auton *et al.*, "A global reference for human genetic variation," *Nature 2015 526:7571*, vol.
 846 526, no. 7571, pp. 68–74, Sep. 2015, doi: 10.1038/nature15393.
- [48] C. Giambartolomei *et al.*, "Bayesian Test for Colocalisation between Pairs of Genetic
 Association Studies Using Summary Statistics," *PLoS Genet*, vol. 10, no. 5, p. e1004383, May
 2014, doi: 10.1371/journal.pgen.1004383.
- 850 [49] S. Purcell *et al.*, "PLINK: A Tool Set for Whole-Genome Association and Population-Based
 851 Linkage Analyses," *The American Journal of Human Genetics*, vol. 81, no. 3, pp. 559–575, Sep.
 852 2007, doi: 10.1086/519795.
- 853 [50] C. Bycroft *et al.*, "The UK Biobank resource with deep phenotyping and genomic data,"
 854 *Nature*, vol. 562, no. 7726, pp. 203–209, 2018.
- [51] C. N. Foley *et al.*, "A fast and efficient colocalization algorithm for identifying shared genetic
 risk factors across multiple traits," *Nat Commun*, vol. 12, no. 1, p. 764, Dec. 2021, doi:
 10.1038/s41467-020-20885-8.
- A. Kamburov, K. Pentchev, H. Galicka, C. Wierling, H. Lehrach, and R. Herwig,
 "ConsensusPathDB: toward a more complete picture of cell biology," *Nucleic Acids Res*, vol.
 39, no. suppl_1, pp. D712–D717, Jan. 2011, doi: 10.1093/NAR/GKQ1156.
- 861[53]G. Hemani *et al.*, "The MR-base platform supports systematic causal inference across the862human phenome," *Elife*, vol. 7, May 2018, doi: 10.7554/ELIFE.34408.
- 863 [54] S. L. Pulit *et al.*, "Meta-analysis of genome-wide association studies for body fat distribution
 864 in 694 649 individuals of European ancestry," *Hum Mol Genet*, vol. 28, no. 1, pp. 166–174,
 865 Jan. 2019, doi: 10.1093/HMG/DDY327.
- 866 [55] C. L. Relton and G. Davey Smith, "Two-step epigenetic Mendelian randomization: a strategy
 867 for establishing the causal role of epigenetic processes in pathways to disease," *Int J*868 *Epidemiol*, vol. 41, no. 1, pp. 161–176, Feb. 2012, doi: 10.1093/IJE/DYR233.
- L. Yengo *et al.*, "Meta-analysis of genome-wide association studies for height and body mass
 index in ~700000 individuals of European ancestry," *Hum Mol Genet*, vol. 27, no. 20, pp.
 3641–3649, Oct. 2018, doi: 10.1093/HMG/DDY271.
- 872 [57] J. Bowden, G. Davey Smith, P. C. Haycock, and S. Burgess, "Consistent Estimation in
 873 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
 874 Estimator," *Genet Epidemiol*, vol. 40, no. 4, pp. 304–314, May 2016, doi: 10.1002/GEPI.21965.
- 875

876

- 877
- 878